These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 12044585)

  • 21. Diabetic dyslipidemia.
    Kreisberg RA
    Am J Cardiol; 1998 Dec; 82(12A):67U-73U; discussion 85U-86U. PubMed ID: 9915665
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparison of lovastatin, an HMG-CoA reductase inhibitor, with gemfibrozil, a fibrinic acid derivative, in the treatment of patients with diabetic dyslipidemia.
    Bell DS
    Clin Ther; 1995; 17(5):901-10. PubMed ID: 8595642
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of dyslipidaemias in patients with established vascular disease: a revival of the fibrates.
    Milionis HJ; Elisaf MS; Mikhailidis DP
    Curr Med Res Opin; 2000; 16(1):21-32. PubMed ID: 16422031
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lipid-lowering drug use and cardiovascular events after myocardial infarction.
    Klungel OH; Heckbert SR; de Boer A; Leufkens HG; Sullivan SD; Fishman PA; Veenstra DL; Psaty BM
    Ann Pharmacother; 2002 May; 36(5):751-7. PubMed ID: 11978147
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Postprandial hypertriglyceridemia and cardiovascular disease: current and future therapies.
    Chan DC; Pang J; Romic G; Watts GF
    Curr Atheroscler Rep; 2013 Mar; 15(3):309. PubMed ID: 23345190
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Niacin as a component of combination therapy for dyslipidemia.
    Miller M
    Mayo Clin Proc; 2003 Jun; 78(6):735-42. PubMed ID: 12934785
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of protease inhibitor-associated hyperlipidemia.
    Penzak SR; Chuck SK
    Am J Cardiovasc Drugs; 2002; 2(2):91-106. PubMed ID: 14727985
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of gemfibrozil or simvastatin on apolipoprotein-B-containing lipoproteins, apolipoprotein-CIII and lipoprotein(a) in familial combined hyperlipidaemia.
    Bredie SJ; Westerveld HT; Knipscheer HC; de Bruin TW; Kastelein JJ; Stalenhoef AF
    Neth J Med; 1996 Aug; 49(2):59-67. PubMed ID: 8824106
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Four years' treatment efficacy of patients with severe hyperlipidemia. Lipid lowering drugs versus LDL-apheresis.
    Schiel R; Bambauer R; Müller UA
    Int J Artif Organs; 1995 Dec; 18(12):786-93. PubMed ID: 8964646
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Antilipemic agents in combined therapy].
    Márk L; Császár A
    Orv Hetil; 2002 Aug; 143(34):1973-8. PubMed ID: 12422650
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of fibrates in the management of hypertriglyceridemia.
    Rader DJ; Haffner SM
    Am J Cardiol; 1999 May; 83(9B):30F-35F. PubMed ID: 10357573
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum magnesium status during lipid-lowering drug treatment in non-insulin-dependent diabetic patients.
    Haenni A; Ohrvall M; Lithell H
    Metabolism; 2001 Oct; 50(10):1147-51. PubMed ID: 11586485
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia.
    Adkins JC; Faulds D
    Drugs; 1997 Oct; 54(4):615-33. PubMed ID: 9339964
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Non-adherence to lipid-lowering therapies: a need for more studies to evaluate reasons for medication non-adherence.
    Wong MC; Wang HH; Liu KS
    Int J Clin Pract; 2011 Dec; 65(12):1321-2. PubMed ID: 22093540
    [No Abstract]   [Full Text] [Related]  

  • 35. Lipid-lowering agents for nephrotic syndrome.
    Kong X; Yuan H; Fan J; Li Z; Wu T; Jiang L
    Cochrane Database Syst Rev; 2013 Dec; (12):CD005425. PubMed ID: 24327265
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Postprandial hemorrheology and apolipoprotein B metabolism in patients with familial hypertriglyceridemia.
    Otto C; Pschierer V; Soennichsen AC; Schwandt P; Richter WO
    Metabolism; 1997 Nov; 46(11):1299-304. PubMed ID: 9361689
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Statins and diabetes.
    Carmena R; Betteridge DJ
    Semin Vasc Med; 2004 Nov; 4(4):321-32. PubMed ID: 15861314
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Managing dyslipidemia in the high-risk patient.
    Stein EA
    Am J Cardiol; 2002 Mar; 89(5A):50C-57C. PubMed ID: 11900720
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia.
    Keating GM; Ormrod D
    Drugs; 2002; 62(13):1909-44. PubMed ID: 12215067
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of fibrates in managing hyperlipidemia: mechanisms of action and clinical efficacy.
    Fazio S; Linton MF
    Curr Atheroscler Rep; 2004 Mar; 6(2):148-57. PubMed ID: 15023300
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.